The company founded in 2006, has been constantly evolving in the development and commercialization of cancer auto-antibody-based assays.
Their line of activities have been growing since their begining, and nowadays comprise, research activities on one side and product design and development activities on the other. Both lines work either for its own proprietary activities and for those of their clients .
Its portfolio includes products and services related with cancer auto-antibody-based assays for cancer diagnosis and clinical management. As the company has began a consolidation stage, they have stablish a double approach for gaining presence in the European market.
Considering their portfolio of products,present on the market, they seek for agents helping them to increase their product sales, and on the other side, they look for new alliances in order to explore synergies and cooperations in new prognosis and diagnosis tools of cancer, offering their technical capacities as services for co-development.
Their product portfolio has been recently updated with new auto-antibodies. Auto-antibodies are antibodies (types of proteins) produced by the immune system that are directed against one or more of the individual's own proteins, such as the tumor antigens present in cancer. Tumor-associated antigens (TAA) can derive from any protein or glycoprotein synthesized by the tumor cell. Tumor proteins can be affected by specific point mutations, misfolding, overexpression, aberrant glycosylation, truncation, or aberrant degradation. Immune system from patients reacts against this TAA’s of the tumor generating several autoantibodies that can be measured in a simple blood test. The advantage of autoantibodies as biomarkers is that they appear at detectable levels in patient’s early blood, allowing earlier diagnosis before symptoms are present and even before other types of biomarkers can be measured. Another auto-antibodies feature that makes them suitable for utilization as biomarkers is their high relative concentrations, extended long half-life and with good stability in blood.
Regarding their auto-antibodies portfolio novelties, they are seeking European life sciences related distributors, in order to set partnerships under distributors or commercial agency agreements.
A second line of activities for the company are offered under service agreements. Counting with a solid team of researchers and technicians, their lab facilities, proprietary equipments and techniques allows them to offer state of the art development services for antibody based assays usually performed under individual customer contracts (CRO).
These services are set for clients with development activities in the fields of:
o Protein expression and purification
o Polyclonal antibody production
o Monoclonal antibody production
o Recombinant antibody Technology
As result of their proprietary developments the company has successfully accomplished their own blood-based diagnostic test for early detection of colorectal cancer (CRC) in population at risk (men and woman 50-75 years old). This non-invasive test shows several technical and economic advantages compared to currently available diagnostic tools that have complexity-related limitations or offer poor detection capacity.
Their experience and expertise in this kind of developments is offered as a service . They seek partnerships with European pharma and biotech companies, and academic or research institutions dealing with prognosis and diagnostic activities of pathologies as cancer (developers and suppliers partners of cancer auto-antibody-based assays) , to cooperate under services or manufacturing agreements.